Sen-Jam Pharmaceutical Innovates with New Patent for Obesity Treatment
Sen-Jam Pharmaceutical has taken a significant step forward in the fight against obesity and metabolic disorders by announcing a groundbreaking patent application. This new patent introduces an innovative composition and method that aims to address the pressing issues of chronic low-grade inflammation, which is often the underlying cause of various metabolic dysfunctions.
The company’s approach involves a synergistic blend of a mast cell stabilizer, an H1-antihistamine, and non-steroidal anti-inflammatory drugs (NSAIDs). These components work together to target the inflammation that contributes heavily to conditions such as obesity and diabetes. By focusing on this crucial link between inflammation and metabolism, Sen-Jam is pushing the boundaries of traditional therapies.
Understanding Chronic Inflammation and Metabolic Disorders
Chronic inflammation can arise due to numerous factors including an unhealthy diet and high stress levels. This state of inflammation can exacerbate conditions like metabolic syndrome and obesity. By utilizing this newly patented methodology, Sen-Jam aims to not only alleviate symptoms but also to manage root causes effectively.
Jackie Iversen, Co-Founder and Chief Clinical Officer, emphasized the importance of this innovation, stating that it has the potential to benefit millions worldwide. "Our approach represents a pivotal advancement in treating obesity and metabolic disorders. We aim to develop treatments that address the core problems without disrupting the body’s natural defenses," she explained.
Impact on Weight Management and Insulin Resistance
This patent details how the innovative combination therapy can lead to a reduction of inflammatory markers, such as C-reactive protein (CRP), and modulate key cytokines linked to metabolic disorders. The approach holds the promise of enhancing weight management, improving insulin sensitivity, and reducing systemic inflammation.
Dr. Francis Farraye, a member of Sen-Jam's advisory board, acknowledges that while the link between inflammation and metabolic disorders is well recognized, more effective treatments are needed. He believes this patent showcases a promising path forward in addressing these interconnected health issues.
Strengthening Sen-Jam's Position in the Pharmaceutical Market
The filing of this patent not only enhances Sen-Jam's intellectual property portfolio but also highlights the company’s commitment to advancing anti-inflammatory care through science. The global market for metabolic and obesity therapeutics is estimated to be worth a staggering $150 billion, signaling significant opportunities for innovation.
Iversen noted, “This patent is an exciting milestone for us. Our platform offers hope for those battling metabolic conditions and signifies a transformative step in the pharmaceutical industry's approach to inflammation-related diseases.”
Engaging with the Healthcare Community
In alignment with its strategic initiatives, the Sen-Jam Pharmaceutical team is set to be present at an upcoming healthcare conference where they plan to engage with investors, partners, and industry leaders. Their goal is to explore avenues for accelerating the development and commercialization of their breakthrough therapies.
All interested parties are encouraged to connect with the team during the conference to discuss potential collaborations. In addition, Sen-Jam is keen on broadening its network and advancing its pipeline of precision anti-inflammatory therapeutics.
About Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is dedicated to pioneering innovative solutions for inflammatory care through its proprietary PAIR (Pleiotropic Anti-Inflammatory Remedies) technology. This technology is designed to target inflammation at its source, using combination therapies that resonate with the body's natural processes.
The company’s mission revolves around enhancing the quality of life, extending health spans, and revolutionizing healing practices worldwide. With a commitment to innovation and partnership, Sen-Jam continues to break new ground in treating inflammation-driven diseases like obesity and metabolic disorders.
CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
Frequently Asked Questions
What is the focus of Sen-Jam Pharmaceutical’s new patent?
The patent focuses on a novel therapeutic approach targeting obesity and metabolic disorders through innovative combinations of existing medications to combat chronic inflammation.
How does chronic inflammation relate to obesity?
Chronic inflammation is linked to metabolic disorders and obesity as it contributes to insulin resistance and other metabolic dysfunctions that exacerbate these conditions.
What are the key components of the new therapy?
The therapy includes a mast cell stabilizer, an H1-antihistamine, and non-steroidal anti-inflammatory drugs (NSAIDs), aiming to synergistically reduce inflammation and support weight management.
What is Sen-Jam's goal with this new patent?
Sen-Jam aims to create effective treatments for obesity and metabolic disorders that address the underlying causes while minimizing the impact on the body's natural immune responses.
Where can I learn more about Sen-Jam Pharmaceutical?
For more information about Sen-Jam Pharmaceutical and its innovative therapeutic approaches, interested individuals can reach out via the provided contact details.
